$npx -y skills add K-Dense-AI/scientific-agent-skills --skill clinical-decision-supportGenerate professional clinical decision support (CDS) documents for pharmaceutical and clinical research settings, including patient cohort analyses (biomarker-stratified with outcomes) and treatment recommendation reports (evidence-based guidelines with decision algorithms). Sup
| 1 | # Clinical Decision Support Documents |
| 2 | |
| 3 | ## Description |
| 4 | |
| 5 | Generate professional clinical decision support (CDS) documents for pharmaceutical companies, clinical researchers, and medical decision-makers. This skill specializes in analytical, evidence-based documents that inform treatment strategies and drug development: |
| 6 | |
| 7 | 1. **Patient Cohort Analysis** - Biomarker-stratified group analyses with statistical outcome comparisons |
| 8 | 2. **Treatment Recommendation Reports** - Evidence-based clinical guidelines with GRADE grading and decision algorithms |
| 9 | |
| 10 | All documents are generated as publication-ready LaTeX/PDF files optimized for pharmaceutical research, regulatory submissions, and clinical guideline development. |
| 11 | |
| 12 | **Note:** For individual patient treatment plans at the bedside, use the `treatment-plans` skill instead. This skill focuses on group-level analyses and evidence synthesis for pharmaceutical/research settings. |
| 13 | |
| 14 | **Writing Style:** For publication-ready documents targeting medical journals, consult the **venue-templates** skill's `medical_journal_styles.md` for guidance on structured abstracts, evidence language, and CONSORT/STROBE compliance. |
| 15 | |
| 16 | ## Capabilities |
| 17 | |
| 18 | ### Document Types |
| 19 | |
| 20 | **Patient Cohort Analysis** |
| 21 | - Biomarker-based patient stratification (molecular subtypes, gene expression, IHC) |
| 22 | - Molecular subtype classification (e.g., GBM mesenchymal-immune-active vs proneural, breast cancer subtypes) |
| 23 | - Outcome metrics with statistical analysis (OS, PFS, ORR, DOR, DCR) |
| 24 | - Statistical comparisons between subgroups (hazard ratios, p-values, 95% CI) |
| 25 | - Survival analysis with Kaplan-Meier curves and log-rank tests |
| 26 | - Efficacy tables and waterfall plots |
| 27 | - Comparative effectiveness analyses |
| 28 | - Pharmaceutical cohort reporting (trial subgroups, real-world evidence) |
| 29 | |
| 30 | **Treatment Recommendation Reports** |
| 31 | - Evidence-based treatment guidelines for specific disease states |
| 32 | - Strength of recommendation grading (GRADE system: 1A, 1B, 2A, 2B, 2C) |
| 33 | - Quality of evidence assessment (high, moderate, low, very low) |
| 34 | - Treatment algorithm flowcharts with TikZ diagrams |
| 35 | - Line-of-therapy sequencing based on biomarkers |
| 36 | - Decision pathways with clinical and molecular criteria |
| 37 | - Pharmaceutical strategy documents |
| 38 | - Clinical guideline development for medical societies |
| 39 | |
| 40 | ### Clinical Features |
| 41 | |
| 42 | - **Biomarker Integration**: Genomic alterations (mutations, CNV, fusions), gene expression signatures, IHC markers, PD-L1 scoring |
| 43 | - **Statistical Analysis**: Hazard ratios, p-values, confidence intervals, survival curves, Cox regression, log-rank tests |
| 44 | - **Evidence Grading**: GRADE system (1A/1B/2A/2B/2C), Oxford CEBM levels, quality of evidence assessment |
| 45 | - **Clinical Terminology**: SNOMED-CT, LOINC, proper medical nomenclature, trial nomenclature |
| 46 | - **Regulatory Compliance**: HIPAA de-identification, confidentiality headers, ICH-GCP alignment |
| 47 | - **Professional Formatting**: Compact 0.5in margins, color-coded recommendations, publication-ready, suitable for regulatory submissions |
| 48 | |
| 49 | ## Pharmaceutical and Research Use Cases |
| 50 | |
| 51 | This skill is specifically designed for pharmaceutical and clinical research applications: |
| 52 | |
| 53 | **Drug Development** |
| 54 | - **Phase 2/3 Trial Analyses**: Biomarker-stratified efficacy and safety analyses |
| 55 | - **Subgroup Analyses**: Forest plots showing treatment effects across patient subgroups |
| 56 | - **Companion Diagnostic Development**: Linking biomarkers to drug response |
| 57 | - **Regulatory Submissions**: IND/NDA documentation with evidence summaries |
| 58 | |
| 59 | **Medical Affairs** |
| 60 | - **KOL Education Materials**: Evidence-based treatment algorithms for thought leaders |
| 61 | - **Medical Strategy Documents**: Competitive landscape and positioning strategies |
| 62 | - **Advisory Board Materials**: Cohort analyses and treatment recommendation frameworks |
| 63 | - **Publication Planning**: Manuscript-ready analyses for peer-reviewed journals |
| 64 | |
| 65 | **Clinical Guidelines** |
| 66 | - **Guideline Development**: Evidence synthesis with GRADE methodology for speci |